Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U.
Main finding: Intravitreal aflibercept dosed monthly or every 2 months after 3 initial monthly doses produced similar efficacy and safety outcomes as monthly ranibizumab.
Purpose: To compare monthly and every-2-month dosing of intravitreal aflibercept injection with with monthly ranibizumab in neovascular AMD.
Study type: Randomized controlled trial
Condition: CNV secondary to AMD
Participants: Active, subfoveal CNV secondary to AMD
n=2419
Intervention:
Group 1: Intravitreal Aflibercept 0.5mg monthly (AFLI 0.5q4)
Group 2: Intravitreal Aflibercept 2mg monthly (AFLI 2q4)
Group 3: Intravitreal Aflibercept 2mg q2monthly after 3 initial monthly doses (AFLI 2q8)
Group 4: Intravitreal Ranibizumab monthly (RAN)
Outcomes
AFLI 0.5q4
AFLI 2q4
AFLI 2q8
RAN
Lost < 15 letters
95.1-95.6%
95.9-96.3%
95.1-95.6%
94.4%
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive